uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study
Duke Univ, Div Cardiol, Durham, NC USA.;Duke Med, Duke Clin Res Inst, Durham, NC USA..
Duke Univ, Div Cardiol, Durham, NC USA.;Duke Med, Duke Clin Res Inst, Durham, NC USA..
Duke Univ, Div Cardiol, Durham, NC USA.;Duke Med, Duke Clin Res Inst, Durham, NC USA..
Univ Paris Diderot, Sorbonne Paris Cite, FACT, DHU,FIRE,AP HP, Paris, France.;INSERM, U1148, Paris, France.;Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, NHLI, London, England..
Show others and affiliations
2016 (English)In: American Heart Journal, ISSN 0002-8703, E-ISSN 1097-6744, Vol. 174, 120-128 p.Article in journal (Refereed) Published
Resource type
Text
Abstract [en]

Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown to be associated with a significant reduction in the composite of cardiovascular death, myocardial infarction, and stroke, and resulted in a nominal reduction in cardiovascular death, when added to background DAPT in the ATLAS ACS 2-TIMI 51 trial; however, there was excessive bleeding with this "triple-therapy" approach. The combination of rivaroxaban with P2Y12 inhibition in a "dual-pathway" approach may be an effective therapeutic regimen for the treatment of ACS, given the known importance of P2Y12 inhibition after stenting and intriguing data that the combination of an anticoagulant with clopidogrel after stenting in patients with atrial fibrillation appears an attractive option to this patient population. GEMINI-ACS-1 is a prospective, randomized, double-dummy, double-blind, active-controlled trial that will assess the safety of dual antithrombotic therapy (rivaroxaban [2.5 mg twice daily] + P2Y12 inhibitor) as compared with DAPT (aspirin [100 mg] + P2Y12 inhibitor) within 10 days of an ACS event in 3,000 patients. Patients will be randomized in a 1: 1 ratio stratified by intended P2Y12 inhibitor use (clopidogrel 75 mg daily or ticagrelor 90 mg twice daily), with 1500 patients expected in each P2Y12 inhibitor strata. The primary end point is Thrombolysis in Myocardial Infarction clinically significant bleeding (major, minor, or requiring medical attention). The exploratory efficacy determination will be a composite of cardiovascular death, myocardial infarction, ischemic stroke, and stent thrombosis. GEMINI-ACS-1 will assess the safety and feasibility of dual antithrombotic therapy with rivaroxaban and a P2Y12 inhibitor compared with conventional DAPT for the treatment for patients with recent ACS.

Place, publisher, year, edition, pages
2016. Vol. 174, 120-128 p.
National Category
Cardiac and Cardiovascular Systems
Identifiers
URN: urn:nbn:se:uu:diva-293003DOI: 10.1016/j.ahj.2016.01.004ISI: 000372538500018PubMedID: 26995378OAI: oai:DiVA.org:uu-293003DiVA: diva2:929223
Available from: 2016-05-18 Created: 2016-05-11 Last updated: 2017-11-30Bibliographically approved

Open Access in DiVA

fulltext(504 kB)102 downloads
File information
File name FULLTEXT01.pdfFile size 504 kBChecksum SHA-512
3cfb08f6b87a7625c9db0bcc59790565c707f343aba3e54b3f639d17efcc1478cfd0c22064f2552d933b2c6dddf064b0d8fd8f36d88c1d9fdca1ab1da8463dd4
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

James, Stefan

Search in DiVA

By author/editor
James, Stefan
By organisation
CardiologyUCR-Uppsala Clinical Research Center
In the same journal
American Heart Journal
Cardiac and Cardiovascular Systems

Search outside of DiVA

GoogleGoogle Scholar
Total: 102 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 570 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf